Cargando…

Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia

SIMPLE SUMMARY: We hereby report on the immunomodulatory effects induced over time in patients with advanced relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphoblastic leukemia (B-ALL) treated with the commercial CAR-T-cell product tisagenlecleucel. We obser...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guarini, Anna, Radice, Giulia, Peragine, Nadia, Buracchi, Chiara, De Propris, Maria Stefania, Di Rocco, Alice, Di Rocco, Arianna, Chiaretti, Sabina, Moretti, Alex, Napolitano, Sara, Martelli, Maurizio, Balduzzi, Adriana, Gaipa, Giuseppe, Biondi, Andrea, Foà, Robin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177375/ https://www.ncbi.nlm.nih.gov/pubmed/37173879 http://dx.doi.org/10.3390/cancers15092411

Ejemplares similares

Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes
por: Messina, Monica, et al.
Publicado: (2016)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Utility of Flow Cytometry Ascitic Fluid Analysis for Rapid Diagnosis of B-Cell Peritoneal Lymphomatosis
por: Bisegna, Maria Laura, et al.
Publicado: (2022)

P1361: SLEEPING BEAUTY PLATFORM FOR ENGINEERING CAR-CIK CELLS TOWARD A MULTI-TARGETING STRATEGY IN B-ALL
por: Moretti, Alex, et al.
Publicado: (2023)

Tisagenlecleucel for B-cell cancers
Publicado: (2019)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
por: Levine, John E, et al.
Publicado: (2021)

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021)

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
por: Freyer, Craig W.
Publicado: (2018)

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
por: Moskop, Amy, et al.
Publicado: (2022)

Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation
por: Ipe, Abraham, et al.
Publicado: (2023)

Myeloid/T-cell acute lymphoblastic leukemia in children and adults
por: Chiaretti, Sabina, et al.
Publicado: (2011)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
por: Ribera Santasusana, Josep Maria, et al.
Publicado: (2020)

SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia
por: Sarno, Jolanda, et al.
Publicado: (2018)

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
por: Laetsch, Theodore W., et al.
Publicado: (2023)

Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: v. Stackelberg, Arend, et al.
Publicado: (2023)

PB1711: DROPLET DIGITAL PCR DETECTION OF THE T315I BCR::ABL1 KD MUTATION IN ADULT PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Cardinali, Deborah, et al.
Publicado: (2023)

Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma
por: Cuffel, Alexis, et al.
Publicado: (2022)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
por: Kwon, Mi, et al.
Publicado: (2022)

Sialylation regulates migration in chronic lymphocytic leukemia
por: Natoni, Alessandro, et al.
Publicado: (2023)

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Bonifacio, Massimiliano, et al.
Publicado: (2022)

Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia
por: Ansuinelli, Michela, et al.
Publicado: (2021)

Diagnosis and Subclassification of Acute Lymphoblastic Leukemia
por: Chiaretti, Sabina, et al.
Publicado: (2014)

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2021)

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns
por: Barsan, Valentin, et al.
Publicado: (2023)

Tisagenlecleucel: Hypogammaglobulinaemia and pancytopenia: case report
Publicado: (2021)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study
por: Boissel, Nicolas, et al.
Publicado: (2023)

Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective
por: Wang, Xiao Jun, et al.
Publicado: (2022)

Tisagenlecleucel: Prolonged neutropenia and thrombocytopenia: case report
Publicado: (2022)

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
por: Goto, Hideki, et al.
Publicado: (2020)

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
por: Jaeger, Ulrich, et al.
Publicado: (2022)

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
por: Bassan, Renato, et al.
Publicado: (2023)

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
por: Pulsipher, Michael A., et al.
Publicado: (2022)

Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS
por: Masucci, Chiara, et al.
Publicado: (2023)

Lineage-tracing methods and the kidney
por: Humphreys, Benjamin D, et al.
Publicado: (2014)

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab
por: Peragine, Nadia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q2jjgan3g649befi9njjet87j8